Abstract:There is considerable interest in the observation that OATP‐mediated transport is significantly increased in the presence of albumin or plasma proteins, a phenomenon called the “protein‐mediated uptake (PMU)” effect (Miyauchi et al., 2018; Liang et al., 2020; Bi et al., 2021). PMU proposes an interaction between the drug‐albumin complex and the cell surface leading to enhanced dissociation of the drug‐albumin complex resulting in increased local unbound drug concentration and therefore an “apparent” increased uptake intrinsic clearance (CLint) (Miyauchi et al., 2018; Kim et al., 2019). This PMU effect helps overcome some (but not all) of the underprediction of hepatic clearance (CL) of OATP drugs by IVIVE. If the PMU hypothesis is correct, the following should be observed in the presence vs. absence of plasma proteins: 1) the active (e.g. by OATP1B1) and passive uptake CLint of the drug should increase to the same extent; and 2) an increase in the slope (i.e. the uptake rate), but not the intercept of the uptake vs. time curve. To determine if the above is true, we determined the total, active (OATP1B1‐mediated) and passive CLint of a cocktail of OATP1B1 drugs [fluvastatin (FLV), pitavastatin (PTV), cerivastatin (CRV), atorvastatin (ATV) and rosuvastatin (RSV)], in the absence and presence of 1%, 2%, or 5% human serum albumin (HSA), by HEK293 MOCK and OATP1B1‐transfected cells at concentrations much less than their reported OATP1B1 Km values. In addition, the unbound drug concentration of each drug, in the absence and presence of HSA, was maintained approximately the same in all experiments. We found: 1) In the presence of HSA, the increase in the passive CLint(i.e. of the unbound drug) was greaterthan for either the total or active uptake CLint of the drug; and 2) in the presence of HSA, the intercept of the uptake curve increased in proportion to the HSA concentration used. An increase in the intercept is usually interpreted as non‐specific binding (NSB) of the drug to the cells/labware; in this case, NSB of the albumin‐drug complex to the cells. Therefore, we asked if PMU can be explained in whole or part by NSB of the albumin‐drug complex to cells or labware? We found that: 1) PMU on passive/active uptake of ATV, FLV and RSV was largely due to NSB (i.e. an artifact). However, it could only partially explain the effect of 5% HSA on OATP1B1‐mediated PTV uptake or the passive uptake of CRV. If the PMU of PTV is a real phenomenon, the unbound inhibitory capacity (IC50,u) of PTV towards OATP1B1 should decrease as the IC50,u is determined ONLY by the interaction between the drug and the transporter and independent of NSB or passive uptake. Indeed, the OATP1B1 IC50,u of PTV (on RSV uptake) in the presence of 5%HSA decreased by 80%, but as expected, that of ATV was unaffected. In conclusion, our results suggests that, except for PTV, the PMU of the drugs studied is likely an artifact. Therefore, mechanisms other than the presence of plasma proteins should be investigated to explain the underprediction of hepatic CL by IVIVE. Reference: Bi YA. et al. (2021) Drug Metabolism and Disposition 49:188–201. Kim SJ. et al. (2019) Drug Metabolism and Disposition 47:94–103. Liang X. et al. (2020) Drug Metabolism and Disposition 48:1283–1292. Miyauchi S. et al. (2018) Drug Metabolism and Disposition 46:259–267.

The potential protein-mediated hepatic uptake: discussion on the molecular interactions between albumin and the hepatocyte cell surface and their implications for the in vitro-to-in vivo extrapolations of hepatic clearance of drugs

A 20-Year Research Overview: Quantitative Prediction of Hepatic Clearance Using the In Vitro-In Vivo Extrapolation Approach Based on Physiologically Based Pharmacokinetic Modeling and Extended Clearance Concept

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Toward a new paradigm for the efficient in vitro–in vivo extrapolation of metabolic clearance in humans from hepatocyte data

Is the Human Model RPTEC/TERT1 a Relevant Model for Assessing Renal Drug Efflux?

Albumin-Mediated Drug Uptake by Organic Anion Transporter 1/3 Is Real: Implications for the Prediction of Active Renal Secretion Clearance

Prediction of Hepatic Plasma Clearance in Vivo from Gel-Entrapped Rat and Human Hepatocytes.

Improving In Vitro-In Vivo Extrapolation (IVIVE) of Clearance Using Rat Liver Microsomes for Highly Plasma Protein Bound Molecules

First-in-Human Predictions of Hepatic Clearance for Drugs With the Well-Stirred Model: Comparative Assessment Between Models of Fraction Unbound Based Either on the Free Drug Hypothesis, Albumin-Facilitated Hepatic Uptake or Dynamic Binding Kinetics

Is Protein‐Mediated Uptake Of Drugs By OATPs, Via Protein‐Lipid Interaction, A Real Phenomenon Or An Artifact?

Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance

An Overview of Interpretability of Two Models of Unbound Fraction that are Used in Combination with the Well-Stirred Model for Predicting Hepatic Clearance of Drugs

In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery

Investigating the Impact of Albumin on the Liver Uptake of Pitavastatin and Warfarin in Nagase Analbuminemic Rats

Is the Protein-Mediated Uptake of Drugs by Organic Anion Transporting Polypeptides a Real Phenomenon or an Artifact?

[Advances and Related Issues in the Use of in Vitro Methods to Predict Metabolic Clearance Rate of New Drugs].

Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions

Usage of In Vitro Metabolism Data for Drug‐Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration

Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach

In Vitro to In Vivo Scalars for Drug Clearance in Non-Alcoholic Fatty Liver and Steatohepatitis

Facing the Facts of Altered Plasma Protein Binding: Do Current Models Correctly Predict Changes in Fraction Unbound in Special Populations?